This week, AbbVie joins the oncology community at the American Society of Clinical Oncology (ASCO) annual meeting to take a closer look at chronic lymphocytic leukemia (CLL). 

NORTH CHICAGO, Ill., June 5, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced safety and preliminary efficacy data from a Phase 1 study of ABT-414 – an investigational antibody drug conjugate (ADC) for epidermal growth factor receptor (EGFR) amplified, recurrent glioblastoma (GBM) – showed no dose-limiting toxicities and frequent, reversible ocular toxicities. Additionally, an estimated 30 percent (n=44) of patients treated with ABT-414 as monotherapy were progression free at six months [95% CI=17, 44] (secondary endpoint). These results, from an expansion cohort of one arm (Arm C) of a three-arm open-label study, were presented today at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.1  Amplified EGFR is the most common genetic mutation associated with malignant GBM, an aggressive brain cancer.2

NORTH CHICAGO, Ill., June 3, 2016 /PRNewswire/ -- At an R&D Day meeting today for the investment community, AbbVie (NYSE: ABBV), a global biopharmaceutical company, will present an overview of its innovative pipeline that reinforces AbbVie's strategy of delivering new therapies that significantly advance and reset the standard of care. Many current therapies in oncology, immunology, virology, neuroscience and women's health are insufficient in meeting the medical needs of patients. In addition, many of the diseases in these therapeutic areas are debilitating, life-threatening and cause a significant burden on healthcare systems around the world.

NORTH CHICAGO, Ill., May 18, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, will present data from multiple clinical trials evaluating the company's portfolio of approved and investigational oncology medicines during the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO), June 3-7, in Chicago. Notably, researchers will present data from studies evaluating Venclexta™ (venetoclax), a BCL-2 inhibitor being developed by AbbVie and Genentech, a member of the Roche Group, and IMBRUVICA® (ibrutinib), an inhibitor of Bruton's tyrosine kinase (BTK), across multiple hematologic malignancies.

NORTH CHICAGO, Ill., May 12, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the UBS Global Healthcare Conference on Monday, May 23, 2016. Bill Chase, executive vice president and chief financial officer, will participate in a question and answer session at 1:00 p.m. Central time.

NORTH CHICAGO, Ill., May 9, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) updated the IMBRUVICA® (ibrutinib) Prescribing Information (PI) to include new data from two Phase 3 trials supporting its expanded use in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).[1] The label now includes overall survival (OS) results in previously-untreated CLL/SLL patients from the Phase 3 RESONATETM-2 (PCYC-1115) trial.

NORTH CHICAGO, Ill., April 29, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion in favor of the use of IMBRUVICA® (ibrutinib) for the treatment of adult patients with previously-untreated chronic lymphocytic leukemia (CLL) in the European Union (EU). The positive CHMP recommendation follows the March 4, 2016 U.S. Food and Drug Administration (FDA) approval of IMBRUVICA for the first-line treatment of patients with CLL.1 If approved by the European Commission (EC), this would be the fifth treatment indication for IMBRUVICA in the EU to date.  

NORTH CHICAGO, Ill., April 29, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Bank of America Merrill Lynch 2016 Global Health Care Conference on Thursday, May 12, 2016. Bill Chase, executive vice president and chief financial officer, will participate in a question and answer session at 1:20 p.m. Central time.

NORTH CHICAGO, Ill., April 28, 2016 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced financial results for the first quarter ended March 31, 2016.

NORTH CHICAGO, Ill., April 28, 2016 /PRNewswire/ -- AbbVie (NYSE:ABBV), a global biopharmaceutical company, announced that it will acquire Stemcentrx and its lead late-stage asset rovalpituzumab tesirine (Rova-T) currently in registrational trials for small cell lung cancer (SCLC). Rova-T is a novel biomarker-specific therapy that is derived from cancer stem cells and targets delta-like protein 3 (DLL3) that is expressed in more than 80 percent of SCLC patient tumors and is not present in healthy tissue. Registrational trials for third-line small cell lung cancer are expected to complete enrollment by the end of 2016.